Activity by Jennifer Schutz
WHAT:Â The Advanced Product Incubator (API) establishes cell-free platforms to develop regenerative therapies. Built according to Current Good Manufacturing Practices (CGMP) set forth by the Food and Drug Administration (FDA), the API adheres to rigorous standards of facility design, monitoring and process control. This multidisciplinary, first-of-its-kind facility bridges teams of researchers and physicians with scientific and industry experts to accelerate product development. The API design fosters the translation of laboratory discoveries into clinical grade curative products developed with the lowest possible risk to patients. APIâ€™s unique approach is to develop low-cost, off-the-shelf, cell-free regenerative therapies that address chronic or incurable diseases. Reporters will have a chance to tour portions of the facility, take photos and video, and interview experts. A ribbon cutting ceremony will take place at 4:30 p.m.
WHERE:Â Minnesota Biobusiness Center, 221 1st Ave. SW, 3rd floor, Rochester, Minnesota.
WHEN:Â Thursday, June 11, 2015, 4:30 to 5:30 p.m.
WHO:Â Interviews available with Atta Behfar, M.D., Ph.D., director, Advanced Product Incubator; Andre Terzic, M.D., Ph.D., director, Mayo Clinic Center for Regenerative Medicine; and Gary Smith, president, Rochester Area Economic Development, Inc.
ROCHESTER, Minn. â€”The American Heart Association (AHA)Â awarded the 2014 Basic Research Prize to Andre Terzic, M.D., Ph.D., of Mayo Clinic. The award, presented at the annual meeting of the American Heart Association in Chicago, recognizes outstanding contributions to the advancement of cardiovascular science. Dr. Terzic was commended for pioneering applications of emerging technologies to advance the diagnosis and treatment of cardiovascular diseases.
â€śIn the year when we celebrate the 100th anniversary of the Division of Cardiovascular Diseases at Mayo Clinic, we are particularly proud that one of our own has been recognized with such a prestigious national award,â€ť says Charanjit Rihal, M.D., chair of Mayo'sÂ Division of Cardiovascular Diseases. â€śDr. Terzic has truly advanced the frontiers of medical science. As a pioneer in cardiac regenerative medicine, he and his team have been at the vanguard of health care.â€ť
â€śAs we look into the future, the pandemic of cardiovascular disease will mandate new solutions, indeed disruptive innovations, to address the unmet needs of patients and populations across the globe,â€ť Dr. Terzic said when he accepted the prize. â€śThe unison of fundamental discovery with clinical translation â€” and ultimately application to populations â€” will provide a guiding principle for generations to come.â€ť
ROCHESTER, Minn. â€” The Mayo Clinic Center for Regenerative Medicine and colleagues at the National University Ireland Galway have signed a formal memorandum of understanding (MOU) to pave the way for joint clinical trials using regenerative therapies.
The MOU follows years of close collaboration with NUI Galwayâ€™s Regenerative Medicine Institute (REMEDI) and the Network of Excellence for Functional Biomaterials (NFB) and will focus on adult stem cell therapy, gene therapy, biomaterials and biomedical engineering. Furthermore, the agreement facilitates ongoing student and staff exchange between Galway and the United States.
Journalists: Sound bites withÂ Dr. WindebankÂ are in the downloads.
ROCHESTER, Minn. â€” Dec. 16, 2013 â€” Mayo Clinic researchers and colleagues in Belgium have developed a specialized catheter for transplanting stem cells into the beating heart. The novel device includes a curved needle and graded openings along the needle shaft, allowing for increased distribution of cells. The result is maximized retention of stem cells to repair the heart. The findings appear in the journal Circulation: Cardiovascular Interventions.Â
â€śAlthough biotherapies are increasingly more sophisticated, the tools for delivering regenerative therapies demonstrate a limited capacity in achieving high cell retention in the heart,â€ť says Atta Behfar, M.D., Ph.D., a Mayo Clinic cardiology specialist and lead author of the study. â€śRetention of cells is, of course, crucial to an effective, practical therapy.â€ť
ROCHESTER, Minn. â€” Sept. 30, 2013Â Â â€”Â Mayo ClinicÂ researchers are part of the second phase of a national consortium that focuses on developing innovative medical treatments for wounded veterans. Mayo's role will emphasize peripheral nerve regeneration. Mayo's principal investigator isÂ Anthony Windebank, M.D., a neurologist and deputy director for discovery in theÂ Mayo Clinic Center for Regenerative Medicine. Other organizations will focus on head and face trauma, burns, transplants and other conditions.
MULTIMEDIA ALERT:Â Video resources, including interviews with Dr. Windebank, are available for journalists at theÂ Mayo Clinic News Network.
"The opportunity to work together with a multidisciplinary, multi-institutional team that will create new therapies for our injured service members is a privilege, and we are proud that Mayo Clinic will be able to make a contribution to this effort," says Dr. Windebank. Other Mayo investigators includeÂ Michael Yaszemski, M.D., Ph.D., biomedical engineering and orthopedics;Â Allen Bishop, M.D., orthopedics;Â Alexander Shin, M.D., orthopedics; andÂ Robert Spinner, M.D., neurologic surgery. [...]
ROCHESTER, Minn. â€”Â Sept. 3, 2013Â â€”Â Mayo ClinicÂ researchers have found a way toÂ resynchronize cardiac motionÂ following aÂ heart attackÂ usingÂ stem cells. Scientists implanted engineered stem cells, also known as induced pluripotent stem (iPS) cells, into damaged regions of mouse hearts following a heart attack. This regenerative approach successfully targeted the origin of abnormal cardiac motion, preventing heart failure. The findings appear in the September issue of theÂ Journal of Physiology.
MULTIMEDIA ALERT: Video resources, including interviews with Drs. Terzic and Yamada, are available for journalists at theMayo Clinic News Network.
"The discovery introduces â€” for the first time â€” stem cell-based 'biological resynchronization' as a novel means to treat cardiac dyssynchrony," saysÂ Andre Terzic, M.D., Ph.D., senior author of the study. Dr. Terzic is the Michael S. and Mary Sue Shannon Family Director,Â Center for Regenerative Medicine, and the Marriott Family Professor of Cardiovascular Diseases Research. [...]
ROCHESTER, Minn. â€” November 28, 2012. Â Next week, more than 1,200 people from 25 countries are expected to attend the 8th Annual World Stem Cell Summit" in West Palm Beach, Fla., a gathering sponsored by Mayo Clinic. As those close to the science explore potential stem cell applications, many patients have questions about what stem cells are and how they are being used. Timothy Nelson, M.D., Ph.D., director of Mayo Clinic's Regenerative Medicine Consult Service, answers some of the most commonly asked questions about stem cells:
MULTIMEDIA ALERT: Multimedia resources, including a Medical Edge package, are available for journalists to download on the Mayo Clinic News Network.
What are stem cells?
Stem cells are the body's raw materials. These cells have the ability to renew themselves or change to become specialized cells with a more specific function, such as blood cells, brain cells, heart muscle or bone.
Where do stem cells come from?
ROCHESTER, Minn. â€” September 25, 2012. Â Mayo Clinic researchers have found a way to detect and eliminate potentially troublemaking stem cells to make stem cell therapy safer. Induced Pluripotent Stem cells, also known as iPS cells, are bioengineered from adult tissues to have properties of embryonic stem cells, which have the unlimited capacity to differentiate and grow into any desired types of cells, such as skin, brain, lung and heart cells. However, during the differentiation process, some residual pluripotent or embryonic-like cells may remain and cause them to grow into tumors.
MULTIMEDIA ALERT: Video resources, including an interview with Dr. Nelson will be available for journalists at the Mayo Clinic News Network.
"Pluripotent stem cells show great promise in the field of regenerative medicine; however, the risk of uncontrolled cell growth will continue to prevent their use as a therapeutic treatment," says Timothy Nelson, M.D., Ph.D., lead author on the study, which appears in the October issue of STEM CELLS Translational Medicine.
Using mouse models, Mayo scientists overcame this drawback by pretreated stem cells with a chemotherapeutic agent that selectively damages the DNA of the stem cells, efficiently killing the tumor-forming cells. The contaminated cells died off, and the chemotherapy didn't affect the healthy cells, Dr. Nelson says.
"The goal of creating new therapies is twofold: to improve disease outcome with stem cell-based regenerative medicine while also ensuring safety. This research outlines a strategy to make stem cell therapies safer for our patients while preserving their therapeutic efficacy, thereby removing a barrier to translation of these treatments to the clinic," says co-author Alyson Smith, Ph.D.